Qiming Stars | Three Qiming Venture Partners Portfolio Companies Selected for 2025 Ifenxi AIGC Vendor Panorama Report
The report aims to reveal how generative AI technology is being applied in specific domains and the core competitive strengths of representative vendors.
Recently, Ifenxi officially released the 2025 Ifenxi AIGC Vendor Panorama Report, aiming to reveal how generative AI (AIGC) technology is being applied in specific domains and the core competitiveness of representative vendors.
Qiming Venture Partners portfolio companies Shengshu Technology, ZuoYi Technology, and Zhipu AI were selected for the report.
Shengshu Technology
(AIGC Marketing)
ZuoYi Technology
(AIGC Healthcare)
Shengshu Technology, Zhipu AI
(AIGC General Assistant, General Foundation Model)
Selected for the
2025 Ifenxi AIGC Vendor Panorama Report
· 2025 Ifenxi AIGC Vendor Panorama Report
To be included in this report, vendors' products and services must meet the capability requirements for each market segment analyzed. Vendors must also have secured a certain number of paying enterprise clients between Q2 2024 and Q1 2025, with revenue in specific markets meeting designated thresholds.
In recent years, generative AI has experienced explosive growth. Globally, tech giants have ramped up their investments in this field, while numerous startups have emerged like mushrooms after rain. Massive capital inflows have accelerated rapid technological iteration and the continuous expansion of application scenarios. Generative AI technology is profoundly transforming how people work and live. The market is expected to maintain high-speed growth in the coming years, becoming one of the key drivers of global digital economic development.
Source | Ifenxi
Past Coverage
Qiming Stars | 4 Qiming Venture Partners Portfolio Companies Named to 2023 Ifenxi Large Model and Digital Innovation Lists Qiming Stars | 10+ Qiming Venture Partners Portfolio Companies Selected for China AI Tech Companies Top 300 List Qiming Honors | Qiming Venture Partners and Investors Named to 36Kr 2025 China Equity Investment Annual Lists
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage outstanding companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. Among these, more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.